{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:34:05Z","timestamp":1756996445004,"version":"3.37.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,7,4]],"date-time":"2009-07-04T00:00:00Z","timestamp":1246665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00296-009-1027-z","type":"journal-article","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T08:05:34Z","timestamp":1246608334000},"page":"613-616","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence of positive ppd in a cohort of rheumatoid arthritis patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Maria Natalia","family":"Tamborenea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Debonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Schijedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,4]]},"reference":[{"key":"1027_CR1","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti tumor necrosis factor alpha monoclonal antibody, and concomitant est\u00e1ndar antirheumatic therapy for treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Artritis). J Rheumatol 30:2563\u20132571","journal-title":"J Rheumatol"},{"key":"1027_CR2","first-page":"1594","volume":"343","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, Van Der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each alone in patients with rheumatoid arthritis: double blinded randomised controlled trial. Lancet 343:1594\u20131602","journal-title":"Lancet"},{"key":"1027_CR3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedvelved FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 342:763\u2013769. doi: 10.1056\/NEJM200003163421103","journal-title":"N Engl J Med"},{"key":"1027_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R et al (2006) The Premier Study: a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337. doi: 10.1002\/art.21519","journal-title":"Arthritis Rheum"},{"key":"1027_CR5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","volume":"46","author":"MC Genovese","year":"2002","unstructured":"Genovese MC, Bothon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two years radiographic and clinical outcomes. Arthritis Rheum 46:1443\u20131450. doi: 10.1002\/art.10308","journal-title":"Arthritis Rheum"},{"key":"1027_CR6","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"K Joseph","year":"2001","unstructured":"Joseph K, Gershon S, Wise PR, Mirabile E et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent. N Engl J Med 345:1098\u20131104. doi: 10.1056\/NEJMoa011110","journal-title":"N Engl J Med"},{"key":"1027_CR7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00002281-200405000-00006","volume":"16","author":"A Imperato","year":"2004","unstructured":"Imperato A, Smiles S, Abramson SB (2004) Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 16:199\u2013205. doi: 10.1097\/00002281-200405000-00006","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"1027_CR8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","volume":"52","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986\u20131992. doi: 10.1002\/art.21137","journal-title":"Arthritis Rheum"},{"key":"1027_CR9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.micinf.2007.02.002","volume":"9","author":"M Jacobs","year":"2007","unstructured":"Jacobs M, Togbe D, Fremond C et al (2007) Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 9:623\u2013628. doi: 10.1016\/j.micinf.2007.02.002","journal-title":"Microbes Infect"},{"key":"1027_CR10","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","volume":"8","author":"H Hamdi","year":"2006","unstructured":"Hamdi H, Marieta X, Godoy V et al (2006) Inhibition of antituberculosis T Lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1027_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0210-5705(03)70338-0","volume":"26","author":"A Obrador","year":"2003","unstructured":"Obrador A, San Roman LA, Mu\u00f1oz P, Gassull MA et al (2003) Guia de Consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 26(1):29\u201333. doi: 10.1157\/13042212","journal-title":"Gastroenterol Hepatol"},{"key":"1027_CR12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","volume":"44","author":"J Ledingham","year":"2005","unstructured":"Ledingham J, Wilkinson C, Deighton C (2005) British Thoracic Society recommendations for assessing risk and managing tuberculosis in patients due to Stara anti-TNF alpha treatments. Rheumatology 44:1205\u20131206. doi: 10.1093\/rheumatology\/kei103","journal-title":"Rheumatology"},{"issue":"suppl III","key":"1027_CR13","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2006.061937","volume":"65","author":"DE Furst","year":"2006","unstructured":"Furst DE, Breedveld FC, Kalden JR et al (2006) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65(suppl III):iii2\u2013iii15. doi: 101136\/ard2006.061937","journal-title":"Ann Rheum Dis"},{"key":"1027_CR14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/rheumatology\/38.12.1203","volume":"38","author":"VM Corrigall","year":"1999","unstructured":"Corrigall VM, Garyfallos A, Panayi GS (1999) The relative proportions of secreted interleukin-2 and interleukin-10 determine the magnitude of rheumatoid arthritis T cell proliferation to the recall antigen tuberculin purified protein derivative. Rheumatol 38:1203\u20131207. doi: 10.1093\/rheumatology\/38.12.1203","journal-title":"Rheumatol"},{"key":"1027_CR15","first-page":"369","volume-title":"Enfermedades Autoinmunes sist\u00e9micas y reumatol\u00f3gicas","author":"E Loza","year":"2005","unstructured":"Loza E, Alen J, Canto F, Alarcon G (2005) Artritis Reumatoide. In: Ramos Casal M, Carrasco M, Salazar J (eds) Enfermedades Autoinmunes sist\u00e9micas y reumatol\u00f3gicas. Masson, Barcelona, pp 369\u2013399"},{"key":"1027_CR16","unstructured":"Fraser P (1999) Micobacterias. In: Fraser RS, Muller NL, Colman N, Pare PD (eds) Diagn\u00f3stico de las Enfermedades del t\u00f3rax, Ed 4\u00ba. WD Sounders, Philadelphia, pp 790\u2013866"},{"key":"1027_CR17","doi-asserted-by":"crossref","unstructured":"Gil Germ\u00e1n, Neira O, Marcone P, Sabagh E (2006) Tuberculine reactivity in chilean RA patients (abstract). J Clin Rheumatol 12(Suppl 4):S8","DOI":"10.1097\/01.rhu.0000226441.71385.45"},{"key":"1027_CR18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","volume":"64","author":"D Ponce de Le\u00f3n","year":"2005","unstructured":"Ponce de Le\u00f3n D, Acevedo-V\u00e1squez E, S\u00e1nchez-Torres A, Cucho M et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360\u20131361. doi: 10.1136\/ard.2004.029041","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1027_CR19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","volume":"67","author":"G Matulis","year":"2008","unstructured":"Matulis G, Juni P, Villiger PM et al (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of mycobacterium tuberculosis antigen-specific interferon assay. Ann Rheum Dis 67(1):84\u201390","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1027_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM200107193450307","volume":"345","author":"PM Small","year":"2001","unstructured":"Small PM, Fujiwara PI (2001) Management of tuberculosis in the United States. N Engl J Med 345(3):189\u2013200","journal-title":"N Engl J Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1027-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-009-1027-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1027-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T17:09:34Z","timestamp":1739207374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-009-1027-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,4]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1007\/s00296-009-1027-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2009,7,4]]}}}